Диссертация (Распространенность, клинические ассоциации, прогностическое значение анемии при сердечной недостаточности в штате Керала, Индия), страница 17
Описание файла
Файл "Диссертация" внутри архива находится в папке "Распространенность, клинические ассоциации, прогностическое значение анемии при сердечной недостаточности в штате Керала, Индия". PDF-файл из архива "Распространенность, клинические ассоциации, прогностическое значение анемии при сердечной недостаточности в штате Керала, Индия", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве РУДН. Не смотря на прямую связь этого архива с РУДН, его также можно найти и в других разделах. , а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата медицинских наук.
Просмотр PDF-файла онлайн
Текст 17 страницы из PDF
// Eur J Heart Fail. – 2016. vol.18(7). – p.786–95.133. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for thetreatment of anemia in patients with chronic heart failure. // J Am CollCardiol. – 2006. - vol.48. – p.1225–1227.134. Toblli JE, Lombran˜ a A, Duarte P, et al. Intravenous iron reduces NTpro-brain natriuretic peptide in anemic patients with chronic heart failureand renal insufficiency.
// J Am Coll Cardiol. – 2007. - vol. 50. – p.1657–1665.135. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M,Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C,Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HFInvestigators. Beneficial effects of long-term intravenous iron therapy withferric carboxymaltose in patients with symptomatic heart failure and irondeficiency.
// Eur Heart J. – 2015. - vol.36(11). – p.657-68.108136. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K,Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA,Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, PonikowskiP. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heartfailure and iron deficiency. // N Engl J Med. – 2009. - vol.361. – p.2436–2448.137. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, deAlbuquerque D, et al.
IRON-HF study: a randomized trial to assess theeffects of iron in heart failure patients with anemia. // Int J Cardiol. – 2013. vol.168(4). – p.3439–42.138. Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletionon exercise capacity in patients with heart failure with reduced ejectionfraction and iron deficiency: the IRONOUT HF randomized clinical trial. //JAMA. – 2017.
- vol.317. – p.1958-1966.139. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, PonikowskiP. Iron deficiency and heart failure: diagnostic dilemmas and therapeuticperspectives. // Eur Heart J. – 2013. - vol.34. – p.816–826.140. Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S,Oles ́kowska-Florek W, Zymlin ́ski R, Biegus J, Siwołowski P, Banasiak W,Anker SD, Filippatos G, Cleland JGF, Ponikowski P. Iron deficiencydefined as depleted iron stores accompanied by unmet cellular ironrequirements identifies pa- tients at the highest risk of death after an episodeof acute heart failure. Eur Heart J.
– 2014. - vol.35. – p.2468 – 2476.141. Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W,von Haehling S, Macdougall IC, Weiss G, McMurray JJV, Anker SD,Gheorghiade M, Ponikowski P. Iron status in patients with chronic heartfailure. // Eur Heart J. – 2013. - vol.34. – p.827 – 834.109142.
Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS.Effect of erythropoietin on exercise capacity in patients with moderate tosevere chronic heart failure. // Circulation. – 2003. - vol.107(2). – p.294–299.143. Van der Meer P, Groenveld H, Januzzi JL, Van Veldhuisen DJ.Erythropoietin Treatment in Patients with Chronic Heart Failure: a metaanalysis. // Heart.
– 2009. - vol.95(16). – p.1309-14144. Silverberg DS, Wexler D, Iaina A, Schwartz D. The role of correction ofanaemia in patients with congestive heart failure: a short review. // Eur JHeart Fail. – 2008. - vol.10(9). – p.819–823.145. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trialof darbepoetin alfa in patients with symptomatic heart failure and anemia. //Circulation. – 2008.
- vol.117(4). – p.526–535.146. Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized,double-blind, placebo-controlled study to evaluate the effect of two dosingregimens of darbepoetin alfa in patients with heart failure and anaemia. //Eur Heart J. – 2007. - vol.28(18). – p.2208–2216.147. Van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin inducesneovascularization and improves cardiac function in rats with heart failureafter myocardial infarction.
// J Am Coll Cardiol. – 2005. - vol.46(1). –p.125–133.148. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous ironwithout erythropoietin for the treatment of iron deficiency anemia in patientswith moderate to severe congestive heart failure and chronic kidneyinsufficiency. // J Nephrol. – 2008. - vol.21(2). – p.236–242.110149.
Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin onexercise capacity in patients with moderate to severe chronic heart failure. //Circulation. – 2003. vol. 107. – p.294–299.150. Palazzuoli A, Silverberg DS, Iovine F, et al. Effects of beta-erythropoietintreatment on left ventricular remodeling, systolic function, and B-typenatriuretic peptide levels in patients with the cardiorenal anemia syndrome.// Am Heart J.
– 2007. - vol.154. – p.e9–e15.151. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfaon exercise tolerance in anemic patients with symptomatic chronic heartfailure: a randomized, double-blind, placebo-controlled trial. // J Am CollCardiol. – 2007. - vol. 49. – p.753–762.152. Dru¨eke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobinlevel in patients with chronic kidney disease and anemia. // N Engl J Med.
–2006. - vol.355. – p.2071–2084.153. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, MaggioniAP, McMurray JJV, O’Connor C, Pfeffer MA, Solomon SD, Sun Y,Tendera M, van Veldhuisen DJ. Treatment of anemia with darbepoetin alfain systolic heart failure. // N Engl J Med. – 2013.
- vol. 368. – p.1210–1219154. Arnold JM, Howlett JG, Dorian P, et al. Canadian Cardiovascular SocietyConsensus Conference recommendations on heart failure update 2007:Prevention,managementduringintercurrentillnessoracutedecompensation, and use of biomarkers. // Can J Cardiol. – 2007. vol.23(1). – p.21–45.155. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized,controlled clinical trial of transfusion requirements in critical care.Transfusion Requirements in Critical Care Investigators, Canadian CriticalCare Trials Group.
// N Engl J Med. – 1999. - vol.340(6). – p.409–417.111156. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusionand clinical outcomes in patients with acute coronary syndromes. // JAMA.– 2004. - vol.292. – p.1555–1562.157. Singh A.K., Szczech L., Tang K.L. et al. Correction of anemia withepoetin alfa in chronic kidney disease. // New Engl J Med. – 2006. – 355. –Р. 2085-2098.158. Szczech LA, Barnhart HX, Inrig JK, et al.
Secondary analysis of theCHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. //Kidney Int. – 2008. - vol.74(6). – p.791–798.159. Moe GW, Ezekowitz JA, O’Meara E, et al. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update:anemia, biomarkers, and recent therapeutic trial implications. // Can JCardiol. – 2015. - vol.31. – p.3-16.26.160. Arocha Rodulfo JI, Navas Blanco T, Amair M.P, Gómez Berroterán R.Clinical implications of iron deficiency in heart failure, an approach to thetreatment.
// Rev. Colomb. Nefrol. – 2016. – vol.3(1). – p. 24-37. doi:10.22265/acnef.3.1.238.161. Makubi A, Roberts DJ. Investigation and treatment for iron deficiency inheart failure: the unmet need in Lower and Middle Income Countries. Br JHaematol. // 2017. – vol.177(6). – p.896-904. doi: 10.1111/bjh.14650.162. Makubi, A., Hage, C., Lwakatare, J. et al, Prevalence and prognosticimplications of anaemia and iron deficiency in Tanzanian patients with heartfailure.
// Heart. – 2015. – vol.101. – p.592–599.163. Alan S Go, Grace H Tabada, Thomas K Leong, Jerry Gurwitz, AndrewArtz, Stanley Schrier, Sunil V Rao, Huiman Barnhart, Kristi Reynolds,David H Smith, Pamela N Peterson, Sue Hee Sung, Harvey J Cohen.112Incidence and Predictors of Anemia Complicating Heart Failure: The RBCHEART Study. // Circulation. – 2017. - vol.136. – p.A14167164. Почечнаягемодинамикаубольныххроническойсердечнойнедостаточностью.
/ Резник Е.В., Гендлин Г.Е., Сторожаков Г.И.,Волынкина В.М.// Журнал Сердечная Недостаточность. – 2007. -№8(3). – С. 118-25.165. Mwita JC, Magafu MGMD, Omech B, Dewhurst MJ, Mashalla Y.Anaemia, renal dysfunction and in-hospital outcomes in patients with heartfailure in Botswana. // S Afr Med J. – 2017. - vol.108(1). – p.56-60.113.
